# Pacira BioSciences, Inc.: overview

PCRX · Nasdaq · CIK 1396814 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pcrx.md) · [Financials](/companies/pcrx/financials.md) · [Filings](/companies/pcrx/filings.md) · [Insiders](/companies/pcrx/insiders.md)

Latest reported revenue: [$192.4m](/filings/0001628280-26-052635.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-052635).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [169](/filings/0001628280-25-050176.md) | [187 d](/filings/0001628280-26-012297.md) | [169](/filings/0001628280-26-028871.md) | [181](/filings/0001628280-26-052635.md) | [180](/filings/0001628280-25-050176.md) | [197 d](/filings/0001628280-26-012297.md) | [177](/filings/0001628280-26-028871.md) | [192](/filings/0001628280-26-052635.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(82.8%)](/filings/0001628280-25-050176.md) | [13.2% d](/filings/0001628280-26-012297.md) | [1.2%](/filings/0001628280-26-028871.md) | [4.7%](/filings/0001628280-26-052635.md) | [3.5%](/filings/0001628280-25-050176.md) | [1.2% d](/filings/0001628280-26-012297.md) | [3.9%](/filings/0001628280-26-028871.md) | [2.2%](/filings/0001628280-26-052635.md) |
| Net margin | % | [(85.1%)](/filings/0001628280-25-050176.md) | [8.6% d](/filings/0001628280-26-012297.md) | [2.8%](/filings/0001628280-26-028871.md) | [(2.7%)](/filings/0001628280-26-052635.md) | [3.0%](/filings/0001628280-25-050176.md) | [0.8% d](/filings/0001628280-26-012297.md) | [1.6%](/filings/0001628280-26-028871.md) | [2.4%](/filings/0001628280-26-052635.md) |
| Diluted EPS | $ per share | [(3.11)](/filings/0001628280-25-050176.md) | not reported | [0.10](/filings/0001628280-26-028871.md) | [(0.11)](/filings/0001628280-26-052635.md) | [0.12](/filings/0001628280-25-050176.md) | not reported | [0.07](/filings/0001628280-26-028871.md) | [0.12](/filings/0001628280-26-052635.md) |
| Free cash flow | $m | [49.8 d](/filings/0001628280-25-050176.md) | [31.0 d](/filings/0001628280-26-012297.md) | [26.9](/filings/0001628280-26-028871.md) | [9.3 d](/filings/0001628280-26-052635.md) | [57.0 d](/filings/0001628280-25-050176.md) | [43.5 d](/filings/0001628280-26-012297.md) | [23.0](/filings/0001628280-26-028871.md) | [56.1 d](/filings/0001628280-26-052635.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [542](/filings/0001396814-24-000030.md) | [667](/filings/0001396814-24-000030.md) | [675](/filings/0001628280-26-012297.md) | [701](/filings/0001628280-26-012297.md) | [726](/filings/0001628280-26-012297.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [16.6%](/filings/0001396814-24-000030.md) | [9.0%](/filings/0001396814-25-000041.md) | [13.0%](/filings/0001628280-26-012297.md) | [(10.5%)](/filings/0001628280-26-012297.md) | [2.6%](/filings/0001628280-26-012297.md) |
| Net margin | % | [7.8%](/filings/0001396814-24-000030.md) | [2.4%](/filings/0001396814-25-000041.md) | [6.2%](/filings/0001628280-26-012297.md) | [(14.2%)](/filings/0001628280-26-012297.md) | [1.0%](/filings/0001628280-26-012297.md) |
| Diluted EPS | $ per share | [0.92](/filings/0001396814-24-000030.md) | [0.34](/filings/0001396814-25-000041.md) | [0.89](/filings/0001628280-26-012297.md) | [(2.15)](/filings/0001628280-26-012297.md) | [0.16](/filings/0001628280-26-012297.md) |
| Free cash flow | $m | [79.9](/filings/0001396814-24-000030.md) | [115](/filings/0001396814-25-000041.md) | [139](/filings/0001628280-26-012297.md) | [179](/filings/0001628280-26-012297.md) | [137](/filings/0001628280-26-012297.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pcrx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $170.1m | 6,705,809 |  | Reduced −29,534 |
| [Doma Perpetual Capital Management LLC](/funds/1962221.md) | 2026-06-30 | $70.5m | 2,777,794 |  | Unchanged |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $61.0m | 2,406,238 |  | Reduced −95,048 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $53.4m | 2,103,245 |  | Added +42,648 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $52.3m | 2,059,977 |  | Added +140,367 |
| [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $49.5m | 1,950,332 |  | Reduced −32,392 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $44.0m | 1,733,801 |  | Reduced −91,700 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $42.9m | 1,691,571 |  | Reduced −92,478 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $38.7m | 1,527,129 |  | Reduced −42,787 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $29.4m | 1,158,693 |  | Added +14,873 |

## Recent filings

[All 1,292 filings](/companies/pcrx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-13 | 17:54 ET | [SCHEDULE 13D/A](/filings/0001104659-26-115589.md) | Ownership report, active investor, amended | 0001104659-26-115589 |
| 2026-10-08 | 09:24 ET | [8-K](/filings/0001104659-26-114571.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-114571 |
| 2026-08-04 | 16:30 ET | [10-Q](/filings/0001628280-26-052635.md) | Quarterly report, period 2026-06-30 | 0001628280-26-052635 |
| 2026-08-04 | 16:03 ET | [8-K](/filings/0001628280-26-052527.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-052527 |
| 2026-06-30 | 07:31 ET | [8-K](/filings/0001628280-26-046136.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-046136 |
| 2026-06-11 | 16:32 ET | [8-K](/filings/0001628280-26-042525.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-042525 |
| 2026-04-30 | 16:07 ET | [10-Q](/filings/0001628280-26-028871.md) | Quarterly report, period 2026-03-31 | 0001628280-26-028871 |
| 2026-04-30 | 16:03 ET | [8-K](/filings/0001628280-26-028854.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-028854 |
| 2026-03-12 | 19:57 ET | [SCHEDULE 13D/A](/filings/0001011438-26-000180.md) | Ownership report, active investor, amended | 0001011438-26-000180 |
| 2026-02-26 | 16:16 ET | [10-K](/filings/0001628280-26-012297.md) | Annual report, period 2025-12-31 | 0001628280-26-012297 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-012297.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/8e839ee4-58d6-457a-aae5-f61a3576c8ec)

## About the filer

- CIK: 1396814
- Tickers: PCRX
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 12:40 ET. No prices; not investment advice.